Olympus Unveils Comprehensive Strategy to Transform Endoscopy-Enabled Care Through Innovation and Workforce Optimization

Olympus Corporation has unveiled a comprehensive corporate strategy aimed at transforming endoscopy-enabled care through technological innovation and operational excellence. The global MedTech company plans to accelerate cutting-edge technologies while reinforcing its leadership position in the medical technology sector, with the ultimate goal of improving outcomes for millions of patients worldwide.

Bob White, Representative Executive Officer, President and Chief Executive Officer at Olympus, described the announcement as a pivotal moment for the company. The strategy builds on Olympus's industry-leading installed base of endoscopy systems to transition beyond hardware toward intelligent, integrated care solutions. Organizational simplification efforts are expected to enhance agility while supporting bold investments in next-generation medical technology.

The company's vision centers on advancing minimally invasive endoscopy through artificial intelligence, robotics, and connected digital ecosystems. This technological evolution aims to enable earlier disease detection, improve clinical outcomes, enhance patient safety, and ensure continuity of care throughout the treatment pathway. With the world's largest installed base of endoscopy systems and significant unmet clinical needs, Olympus positions itself uniquely to scale innovation globally and redefine standards in endoscopy-enabled care.

The strategic framework rests on three core pillars: Innovation-driven Growth, Simplicity, and Accountability. The innovation component focuses on expanding leadership in AI-powered endoscopy, robotics, and cloud-connected solutions. Meanwhile, simplicity and accountability serve as operational accelerators designed to streamline processes, empower teams, and drive sustainable performance improvements across the organization.

As part of the strategic implementation, Olympus will undergo a global organizational transformation aligning structure and resources with strategic priorities. The company anticipates these changes will generate approximately 24 billion yen in run rate savings and result in a net reduction of roughly 2,000 positions in the global workforce. The optimization initiative will simplify organizational layers and expand managerial spans of control, fostering greater agility and clearer accountability throughout the company.

Financially, Olympus has established a three-year plan targeting 5% year-on-year revenue growth by fiscal year 2029, annual 100 basis-point growth beginning in fiscal year 2026, more than 10% EPS compound annual growth rate, and continuous improvement in free cash flow. Capital deployment will support innovation initiatives, dividends, share buybacks, and strategic mergers and acquisitions.

Leadership transitions accompany the strategic announcement, with Keith Boettiger scheduled to become Executive Officer and Gastrointestinal Solutions Division Head effective April 1, 2026. He will succeed Frank Drewalowski, who will transition to Senior Advisor to the Chief Executive Officer. Yasuo Takeuchi will step down as Representative Executive Officer, Executive Chairperson and ESG Officer at the end of March 2026, concluding over four decades of service during which he led Olympus's transformation into a pure-play MedTech company. Additional information about the company's initiatives can be found at https://www.olympus-global.com.